ACHE and Alzheimer disease: Moreover, the debate over the clinical utility and cost-effectiveness of the major drugs used to treat AD, the most common neurodegenerative diseases (e.g. AChE inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists), has existed for decades as these drugs are not of benefit for all patients and long-term users are more likely to experience severe adverse drug reactions [1, 23, 24].